Weal and woe of interleukin-18 in the T cell therapy of cancer

Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a do...

Full description

Saved in:
Bibliographic Details
Main Authors: Christoph Kessel, Hinrich Abken, Claudia Rossig
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e010545.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items